- Home
- NEUP vs ICU Comparison
NEUP vs ICU Comparison
Compare NEUP & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEUP
- ICU
- Stock Information
- Founded
- NEUP 1996
- ICU 2018
- Country
- NEUP United States
- ICU United States
- Employees
- NEUP N/A
- ICU N/A
- Industry
- NEUP
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- NEUP
- ICU Health Care
- Exchange
- NEUP Nasdaq
- ICU Nasdaq
- Market Cap
- NEUP 14.7M
- ICU 15.9M
- IPO Year
- NEUP N/A
- ICU N/A
- Fundamental
- Price
- NEUP $4.55
- ICU $0.57
- Analyst Decision
- NEUP Strong Buy
- ICU
- Analyst Count
- NEUP 2
- ICU 0
- Target Price
- NEUP $28.00
- ICU N/A
- AVG Volume (30 Days)
- NEUP 4.7M
- ICU 1.3M
- Earning Date
- NEUP 11-21-2025
- ICU 11-13-2025
- Dividend Yield
- NEUP N/A
- ICU N/A
- EPS Growth
- NEUP N/A
- ICU N/A
- EPS
- NEUP N/A
- ICU N/A
- Revenue
- NEUP $15,649,448.00
- ICU $766,000.00
- Revenue This Year
- NEUP N/A
- ICU $820.00
- Revenue Next Year
- NEUP N/A
- ICU $63.37
- P/E Ratio
- NEUP N/A
- ICU N/A
- Revenue Growth
- NEUP N/A
- ICU N/A
- 52 Week Low
- NEUP $2.90
- ICU $0.31
- 52 Week High
- NEUP $126.00
- ICU $3.39
- Technical
- Relative Strength Index (RSI)
- NEUP 33.43
- ICU 40.80
- Support Level
- NEUP $4.53
- ICU $0.60
- Resistance Level
- NEUP $8.44
- ICU $0.65
- Average True Range (ATR)
- NEUP 1.19
- ICU 0.05
- MACD
- NEUP -1.03
- ICU 0.00
- Stochastic Oscillator
- NEUP 5.65
- ICU 26.67
About NEUP Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.